Results 211 to 220 of about 941,777 (314)

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Sunshine Act expansion and the prescription of generic medications by advanced practice providers. [PDF]

Health Aff Sch
Nadeem H, Li J, Donovan LM, Feemster LC, Au DH, Duan KI.   +5 more
europepmc   +1 more source

A Medicinal Chemist’s Perspective on Transitioning from Industry to Academic Drug Discovery

, 2019
James C. Barrow
openalex   +2 more sources

Predicting Loss of Ambulation in Limb Girdle Muscular Dystrophy R9

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Limb girdle muscular dystrophy type R9 (LGMDR9) results from biallelic variants in FKRP. There is limited data to predict loss of ambulation (LOA) among those with LGMDR9. Methods Participants in an ongoing dystroglycanopathy natural history study (NCT00313677) with FKRP variants who had achieved ambulation and were more than 3 ...
Chandra L. Miller, Lauren N. Coffey, Shelley R. H. Mockler, Katie M. Laubscher, Carrie M. Stephan, M. Bridget Zimmerman, Katherine D. Mathews   +6 more
wiley   +1 more source

Evaluating the corporate social responsibility agenda for high-cost novel therapies: roles for government and civil society. [PDF]

Health Res Policy Syst
Wong A, Saeed G, Garner S, Kohler J.
europepmc   +1 more source

Greening a Drug-Addicted Economy: Can Puerto Rico Ease Away from the Toxic Pharmaceutical Industry to a Sustainably Diverse Economy?

, 2015
Natalie Galarza
openalex   +1 more source

Drug firms hype disease as sales ploy, industry chief claims

, 2002
R. Moynihan
openalex   +2 more sources

Doctors and the drug industry. [PDF]

, 1983
Sigurður Guðmundsson
openalex   +1 more source

Applying an Ethical Lens to the Treatment of People With Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The practice of neurology requires an understanding of clinical ethics for decision‐making. In multiple sclerosis (MS) care, there are a wide range of ethical considerations that may arise. These involve shared decision‐making around selection of a disease‐modifying therapy (DMT), risks and benefits of well‐studied medications in comparison to
Methma Udawatta, Farrah J. Mateen
wiley   +1 more source